Henshaw Capital’s Haemonetics HAE Stock Holding History

Henshaw Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-8,292	Closed	-$290K	–	265
2016 Q1	$290K	Buy	+8,292	New	+$268K	0.04%	195

Other funds holding HAE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

Henshaw Capital's HAE Position: Q2 2016 in Review

Henshaw Capital sold out of Haemonetics (HAE) in Q2 2016, closing a stake of 8,292 shares — an estimated $290K sold.

Henshaw Capital first reported a position in HAE in Q1 2016 and held it in 1 quarter. The position peaked at $290K in Q1 2016. 178 funds tracked by Wall St. Rank hold HAE as of Q2 2016.

Henshaw Capital reported no remaining Haemonetics position as of Q2 2016 after selling out during the quarter.
Henshaw Capital sold 8,292 Haemonetics shares in Q2 2016, an estimated $290K.
Henshaw Capital first reported a position in Haemonetics in Q1 2016 and held it in 1 quarter.
Henshaw Capital's Haemonetics position peaked at $290K in Q1 2016.
178 funds tracked by Wall St. Rank held Haemonetics as of Q2 2016.

Based on Henshaw Capital's 13F filing for Q2 2016, filed 28 May 2026.